<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04289051</url>
  </required_header>
  <id_info>
    <org_study_id>CLP-2020-02-01-1</org_study_id>
    <nct_id>NCT04289051</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of Oral Rinse for Xerostomia</brief_title>
  <official_title>Clinical Evaluation of the Efficacy of an Intra Oral Rinse for Patients With Xerostomia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunstar Americas</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunstar Americas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Xerostomia causes a difficulty in eating, have irritated oral tissues, and a poor quality of&#xD;
      life. The new oral rinse was designed to reduce the symptoms and improve the patient's&#xD;
      quality of life. The objectives of the clinical study is to evaluate the effectiveness of the&#xD;
      oral rinse comparing to the placebo product and the control product in the market.&#xD;
&#xD;
      This is a randomized double-blind placebo controlled crossover study with 39 patients&#xD;
      receiving treatment. Patients will be randomly allocated to three treatment groups. Patients&#xD;
      will use the assigned oral rinse four times a day for two weeks. Dry mouth symptoms and other&#xD;
      endpoints will be assessed subjectively and objectively at baseline and Day 14. Patients will&#xD;
      be assigned to another treatment after one week wash-out period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 19, 2020</start_date>
  <completion_date type="Actual">February 4, 2021</completion_date>
  <primary_completion_date type="Actual">February 4, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in dry mouth symptom by Visual Analog Scale at 14 days</measure>
    <time_frame>Baseline, 14 days</time_frame>
    <description>10 cm scale for subjective scoring the level of dry mouth. 0 mm: not dry at all, 10 mm: very dry.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in dry mouth symptoms by xerostomia questionnaire at 14 days</measure>
    <time_frame>Baseline, 14 days</time_frame>
    <description>Questionnaire to assess xerostomia symptoms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in quality of life by Oral Health Impact Profile at 14 days</measure>
    <time_frame>Baseline, 14 days</time_frame>
    <description>Questionnaire to assess quality of life related to oral health</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in oral functions by Revised Oral Assessment Guide at 14 days</measure>
    <time_frame>Baseline, 14 days</time_frame>
    <description>Assessment of oral functions by dental professional</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Xerostomia</condition>
  <arm_group>
    <arm_group_label>HYDRAL Oral Rinse</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects use the oral rinse four times daily adding to a regular oral hygiene routine with a fluoride toothpaste and a soft tooth brush.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIOTENE® Oral Rinse</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects use the oral rinse four times daily adding to a regular oral hygiene routine with a fluoride toothpaste and a soft tooth brush.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Oral Rinse</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects use the oral rinse four times daily adding to a regular oral hygiene routine with a fluoride toothpaste and a soft tooth brush.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HYDRAL Oral Rinse</intervention_name>
    <description>Application 4 times a day for two weeks</description>
    <arm_group_label>BIOTENE® Oral Rinse</arm_group_label>
    <arm_group_label>HYDRAL Oral Rinse</arm_group_label>
    <arm_group_label>Placebo Oral Rinse</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BIOTENE® Oral Rinse</intervention_name>
    <description>Application 4 times a day for two weeks</description>
    <arm_group_label>BIOTENE® Oral Rinse</arm_group_label>
    <arm_group_label>HYDRAL Oral Rinse</arm_group_label>
    <arm_group_label>Placebo Oral Rinse</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo Oral Rinse</intervention_name>
    <description>Application 4 times a day for two weeks</description>
    <arm_group_label>BIOTENE® Oral Rinse</arm_group_label>
    <arm_group_label>HYDRAL Oral Rinse</arm_group_label>
    <arm_group_label>Placebo Oral Rinse</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Must have read, understood and signed an informed consent prior to being entered into&#xD;
             the study.&#xD;
&#xD;
          2. Must be 18 to 80 years of age, male or female.&#xD;
&#xD;
          3. Have at least 20 natural or restored teeth.&#xD;
&#xD;
          4. Have an unstimulated salivary flow rate &lt;0.20 ml/minute which represents a significant&#xD;
             reduction of normal salivary function&#xD;
&#xD;
          5. Must have subjective xerostomia symptom: minimum level of 4 on a 10 centimeters Visual&#xD;
             Analog Scale (VAS) [How would you score dryness of your mouth?]&#xD;
&#xD;
          6. Agree not to have a dental prophylaxis or any other elective, non-emergency dental&#xD;
             procedures (other than those provided during the study) any time during the study.&#xD;
&#xD;
          7. Agree to abstain from the use of any products for xerostomia other than those provided&#xD;
             in the study.&#xD;
&#xD;
          8. Agree to comply with the conditions and schedule of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Physical limitations or restrictions that might preclude normal tooth brushing.&#xD;
&#xD;
          2. Evidence of gross oral pathology, including widespread caries or chronic neglect,&#xD;
             extensive restoration, pre-existing gross plaque or soft or hard tissue tumor of the&#xD;
             oral cavity.&#xD;
&#xD;
          3. Presence of severe gingivitis with 30 or more sites showing bleeding on probing.&#xD;
&#xD;
          4. Evidence of major oral hard or soft tissue lesions or trauma at the baseline visit as&#xD;
             determined by the Investigator/Examiner.&#xD;
&#xD;
          5. Chronic disease with concomitant oral manifestations other than xerostomia&#xD;
&#xD;
          6. Conditions requiring antibiotic treatment prior to dental prophylaxis and invasive&#xD;
             procedures, such as heart murmur, history of rheumatic fever, valvular disease or&#xD;
             certain prosthetic implants.&#xD;
&#xD;
          7. History of hepatic or renal disease, uncontrolled diabetes, or other serious&#xD;
             conditions or transmittable diseases.&#xD;
&#xD;
          8. Subjects who are currently undergoing, or require, extensive dental work, orthodontic&#xD;
             treatment or periodontal surgery or orthodontic treatment in the preceding 3 months&#xD;
&#xD;
          9. Currently using bleaching trays&#xD;
&#xD;
         10. History of radiotherapy, head and neck cancer or Sjogren's syndrome.&#xD;
&#xD;
         11. History of significant adverse effects following use of oral hygiene products such as&#xD;
             toothpastes and mouthrinses.&#xD;
&#xD;
         12. Subjects who are nursing, pregnant or plan to become pregnant for the duration of the&#xD;
             study.&#xD;
&#xD;
         13. Currently breast feeding&#xD;
&#xD;
         14. Eating disorders&#xD;
&#xD;
         15. Recent history of substance abuse&#xD;
&#xD;
         16. Participation in other clinical studies within 14 days of screening&#xD;
&#xD;
         17. Smoking &gt;10 cigarettes/day&#xD;
&#xD;
         18. Chewing tobacco&#xD;
&#xD;
         19. Daily use of symptom alleviating products against xerostomia within 7 days of&#xD;
             screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University at Buffalo, The Center for Dental Studies</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 26, 2020</study_first_submitted>
  <study_first_submitted_qc>February 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2020</study_first_posted>
  <last_update_submitted>April 8, 2021</last_update_submitted>
  <last_update_submitted_qc>April 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Xerostomia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

